Navigation Links
Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist
Date:4/20/2009

Trial Will Evaluate Safety, Proof of Mechanism of a Potential Oral Antagonist for the Treatment of Asthma and COPD

SAN DIEGO, April 20 /PRNewswire/ -- Amira Pharmaceuticals, Inc., announced today the initiation of a Phase I clinical study of AM211, its internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway.

AM211 is an oral, selective antagonist of the receptor DP2, which recent studies have shown to be a potential target for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The Phase I study is designed to obtain safety and proof of mechanism data for AM211.

"There remains a great deal of unmet medical need in asthma and COPD, and we look forward to exploring AM211's potential as a new treatment option," said Isabelle DeArmond, M.D., Vice President Clinical Development. "We may also explore AM211 in other inflammatory diseases based on the safety and proof of mechanism data from our Phase I studies."

DP2 is also known as CRTH2 or chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes. DP2 is a high affinity receptor for prostaglandin D2 and, in humans, is implicated in Th2-dependent allergic inflammation.

"The start of the AM211 clinical studies marks another impressive milestone in our company's short existence. Our small but effective team has been able to bring three distinct molecules into the clinic in less than four years," said Bob Baltera, Amira's Chief Executive Officer. "We look forward to continuing this pace as we advance our next program for idiopathic pulmonary fibrosis toward the clinic."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
2. Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor
3. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
4. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
5. Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
6. QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
7. Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug
8. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
9. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
10. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
11. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014 Egenix, Inc. is pleased to ... Chairman of the Board, to succeed Donald Fresne ; ... will continue as a member of the Board.  In recognition ... to the company over almost twenty years, the Board designated ... of Directors has established a Search Committee to find a ...
(Date:12/17/2014)... USA (PRWEB) December 16, 2014 ... manager at Philipps- Universität Marburg’s Department of Physics, ... photonics, in the newly released SPIE Women ... never be too shy to ask questions.” , ... technology, engineering, and mathematics) occupations ranging from university ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... we didnt spend so much time trying to be the next ... Wisconsins technology roadmap is to become a Midwest carbon copy of ... differences in business, labor and general population are so vast that ... and still not come close. If its true that the ...
... , WTN: What's the next big thing in technology? E-commence? ... will be the continuous improvements in CRM tools and software. ... better connecting customers with companies and institutions. All of ... element that surrounds our customers. Doing so will result ...
... about weblogs - until now. Truth be told - and probably ... bandwagons. If everyone is going right, I'll move left just to ... on blogging was that it was just another technology-enabled fad. Any ... other fool could read it. Of course, there was, initially, a ...
Cached Biology Technology:What If We Cut Our Own Path? 2What If We Cut Our Own Path? 3The Next Big Thing in E-Commerce - Guild.com CEO comments on Wisconsin's technology vision 2The Blog Nation 2The Blog Nation 3
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... the coralline algae fossils that lived on the last coral ... years ago. Mediterranean algae and coral reefs began to resemble ... the Indian Ocean and global cooling 15 and 20 million ... University of Granada (UGR) and the University of Modena and ...
... A study comparing how two common dietary oil ... themselves, can lower body fat in obese postmenopausal women ... were safflower oil, a common cooking oil, and conjugated ... meat and dairy products that has been associated with ...
... Antonio Medical mycologists in The South Texas Center ... Biology at The University of Texas at San Antonio ... Valley Fever, a respiratory infection of humans, commonly called ... fungus. For the first time, the researchers ...
Cached Biology News:Coralline algae in the Mediterranean lost their tropical element between 5 and 7 million years ago 2Two dietary oils, two sets of benefits for older women with diabetes 2Two dietary oils, two sets of benefits for older women with diabetes 3Two dietary oils, two sets of benefits for older women with diabetes 4UTSA infectious disease researchers advancing vaccine against Valley fever 2
Request Info...
... the Art GLP facility with capabilities ... L fermentation. Coordinated process development ... Aseptic operation capable of simultaneous production ... Modes. Hosts include: Bacteria, Yeast, ...
ExonBio Service provides one-stop recobinant protein shopping from cloning, expression and purification. Price including gene cloning....
TRBP1 Antibody...
Biology Products: